Confronto
Gonadorelin vs. LL-37
Due peptidi a confronto — identità, base di evidenze, stato legale ed eventi avversi noti.
Identità
Categoria
Ricerca (altro)
Ricerca (altro)
N. CAS
33515-09-2
597562-32-8
Peso molecolare
1182.29 g/mol
4493.33 g/mol
Emivita
0.1 h
nessun dato
Sequenza
pGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTESMeccanismo d'azione
Gonadorelin
Gonadorelin acts as an agonist at the GnRH receptor on the gonadotroph cells of the pituitary and triggers release of the gonadotropins luteinizing hormone (LH) and follicle-stimulating hormone (FSH). The temporal pattern of receptor exposure is decisive: pulsatile administration mimics the natural hypothalamic secretory rhythm and sustains LH/FSH release, whereas continuous exposure leads to receptor internalisation and desensitisation with subsequent paradoxical suppression of gonadotropins. The latter principle is exploited therapeutically by longer-acting GnRH agonists.
LL-37
LL-37 is a cationic, amphipathic helical peptide and the only member of the cathelicidin family in humans. It is generated by proteolytic cleavage from the C-terminal portion of the precursor protein hCAP18 (CAP-18). Mechanistically it associates with and can permeabilize microbial membranes; in addition it modulates immune cells, influences cytokine release, exerts chemotactic activity, and can bind extracellular self-DNA. Preclinical models have described both anti-inflammatory and pro-inflammatory effects, depending on concentration and tissue context.
Base di evidenze
Evidenza più alta
Studio sull'uomo
Studio sull'uomo
Studi
4
4
di cui sull'uomo
4
1
Effetti registrati
4
4
Contraddizioni aperte
1
1
Eventi avversi documentati
2
0
Stato legale
Voci complete
Frequently asked questions
- What is the difference between Gonadorelin and LL-37?
- Gonadorelin is classified as "Ricerca (altro)", while LL-37 is classified as "Ricerca (altro)". Gonadorelin: Gonadorelin is the synthetic decapeptide with an amino-acid sequence identical to endogenous gonadotropin-releasing hormone (GnRH/LHRH). Historically approved in several countries for diagnostic testing of pituitary function and for fertility indications (pump systems). A defining feature is the opposite effect of pulsatile versus continuous administration: pulsatile stimulates, continuous leads to receptor desensitisation. LL-37: LL-37 is the only known human cathelicidin, a 37-amino-acid antimicrobial peptide generated by cleavage of the precursor protein hCAP18. In research it plays a central role in innate immune defence and wound healing, yet acts in a context-dependent manner as both anti- and pro-inflammatory and has been linked to autoimmune processes. LL-37 is not an approved drug; the evidence base is predominantly basic and preclinical. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
- Which peptide is better supported by science, Gonadorelin or LL-37?
- The highest available evidence level is "Studio sull'uomo" for Gonadorelin and "Studio sull'uomo" for LL-37. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
- What is the legal status of Gonadorelin and LL-37 in Germany and the United States?
- Germania: Gonadorelin — Su prescrizione, LL-37 — Solo ricerca. Stati Uniti: Gonadorelin — Su prescrizione, LL-37 — Solo ricerca. These are factual summaries with source and review date on the individual pages.